Kymeris Therapeutics

Company profile

Kymeris Therapeutics company profile

Kymeris is a Canadian biopharmaceutical developer in late pre-Clinical stage for a Eukaryotic Immunotherapeutic Cancer Vaccine that has demonstrated potent therapeutic effect on solid cancers, even at a metastatic level. Our researchers achieved Proofs of Principle in 4 pre-clinical murine models and created multiple derivatives that express or secrete constructs of therapeutic interest. I. Features of our Platforms, demonstrated to date a. Effect on "Cold" tumors (of low immuno-reactivity) b. Overcomes Tumor Microenvironment defenses. The agents can infiltrate the TME, and have shown impressive capacity to reactivate tolerogenic DCs and indices strong Cellular Immune response (Th-I profile), the type that destroys cancerous cells. c.. Flexible Tumor-centric Drug Delivery. Complex transgenic payloads of molecules can be expressed or secreted preferentially inside tumor. Initial derivatives deliver inside tumor: antigenic trigger, antibody or cytokine, They are also capable of vectoring other useful agents through engineering with heterologous genes encoding other molecules of therapeutic value. d. Bodywide effect after Subcutaneous or local administration. The could translate into less-invasive administration protocols including against multi-site or metastases from occult cancerous cells after surgery.